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Heat	 shock	 protein	 105	 (HSP105)	 is	 overexpressed	 in	 many	 cancers,	 including	
colorectal	cancer	(CRC)	and	esophageal	cancer	(EC).	We	carried	out	a	phase	I	clinical	
trial	of	HLA‐A24‐	and	HLA‐A2‐restricted	HSP105	peptide	vaccines	in	patients	with	
CRC	 or	 EC.	 In	 this	 additional	 study	 of	 the	 trial,	 we	 examined	 the	 immunological	
efficacy	of	the	novel	vaccine.	Thirty	patients	with	advanced	CRC	or	EC	underwent	
HSP105	peptide	 vaccination.	 Immunological	 responses	were	 evaluated	by	 ex	 vivo	
and	in	vitro	γ‐interferon	enzyme‐linked	immunospot	assays	and	their	correlation	with	
patients’	 prognosis	was	 analyzed.	 The	HSP105	peptide	 vaccines	 induced	peptide‐







CTLs	was	observed	at	 the	 injection	 sites	 (skin)	 and	 tumor	 tissues,	 suggesting	 that	
HSP105‐specific	CTLs	not	only	accumulated	at	vaccination	sites	but	also	infiltrated	
tumors.	Furthermore,	we	established	2	HSP105	peptide‐specific	CTL	clones,	which	
showed	HSP105‐specific	 cytokine	 secretion	 and	 cytotoxicity.	Our	 results	 suggest	
that	 the	 HSP105	 peptide	 vaccine	 could	 induce	 immunological	 effects	 in	 cancer	
patients	and	improve	their	prognosis.
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1  | INTRODUC TION







































of	 HSP105‐specific	 CTLs	 in	 peripheral	 blood,	 injection	 sites,	 and	
tumor	tissues,	suggesting	that	CTL	induction	could	be	a	prognostic	
biomarker	in	vaccinated	patients	with	advanced	CRC	and	EC.
2  | MATERIAL S AND METHODS
2.1 | Study design
This	 research	was	 undertaken	 as	 an	 additional	 study	 of	 a	 phase	 I	
clinical	 trial	 of	 HSP105‐derived	 peptide	 vaccine.	 Fifteen	 patients	
carrying	the	HLA‐A24	gene	received	HLA‐A24‐restricted	HSP105‐
derived	 peptides	 (A24‐1	 and	A24‐7)	 and	 15	 carrying	 the	HLA‐A2	
gene	 received	 HLA‐A2‐restricted	 HSP105‐derived	 peptides	 (A2‐7	
and	A2‐12)	(Table	S1).	Peptide	vaccines	were	given	with	an	adjuvant	








2.2 | Evaluation of clinical response








Paque	 (Pharmacia),	 frozen	 at	 −80°C,	 and	 stored	 in	 liquid	 nitrogen	
until	use.
2.4 | Cell lines
Human	 colon	 cancer	 cell	 line	 SW620	 (high	 HSP105	 expression,	
HLA‐A*02:01/A*24:02)	and	human	liver	cancer	cell	line	HepG2	(low	
HSP105	 expression,	 HLA‐A*02:01/A*24:02)	 were	 used	 as	 target	





or	 DMEM	 (Sigma)	 supplemented	 with	 10%	 heat‐inactivated	 FBS	
(Gibco)	 and	 1%	 penicillin	 and	 streptomycin	 (Gibco)	 at	 37°C	 in	 a	
humidified	atmosphere	containing	5%	CO2.
2.5 | Ex vivo IFN‐γ ELISPOT assay
The	 BD	 ELISPOT	 kit	 (BD	 Biosciences)	 was	 used	 according	 to	 the	
manufacturer's	 instructions.	Noncultured	 PBMCs	 (5	 ×	 105	 per	well)	
were	incubated	with	peptide	antigens	(10	μg/mL)	for	20	hours	at	37°C	
and	 5%	 CO2.	 The	 following	 HSP105	 antigens	 were	 used:	 HLA‐A2‐
restricted	 A2‐7	 (RLMNDMTAV)	 or	 A2‐12	 (KLMSSNSTDL)	 for	 HLA‐
A2‐positive	 PBMCs	 and	 HLA‐A24‐restricted	 A24‐1	 (NYGIYKQDL)	
or	 A24‐7	 (EYVYEFRDKL)	 for	 HLA‐A24‐positive	 PBMCs.	 The	
PBMCs	 incubated	 with	 HLA‐A2‐restricted	 HIV19‐27	 (TLNAWVKVV)	
or	 HLA‐A*24:02‐restricted	 HIV583‐591	 (RYLKDQQLL)	 peptides	
(ProImmune)	were	used	as	negative	control.	The	number	of	CTL	spots	
was	calculated	automatically	by	the	Eliphoto	system	(Minerva	Tech).	
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To	 eliminate	 nonspecific	 immune	 responses	 unrelated	 to	 HSP105	




HSP105	and	HIV	peptides	was	 less	 than	30	 spots,	 the	 results	were	
excluded.	All	analyses	were	carried	out	in	duplicate.
2.6 | Induction of HSP105 peptide‐specific CTLs 
from PBMCs and in vitro IFN‐γ ELISPOT assay











HIV	peptides	 and	 less	 than	10‐spot	 differences	 between	HSP105	
and	HIV	peptides	were	excluded.	All	 analyses	were	 carried	out	 in	
duplicate.
2.7 | Dextramer staining
The	PBMCs	 stimulated	with	 each	peptide	were	 stained	with	HLA	
type‐matched	Dextramer‐RPE	for	10	minutes	at	room	temperature.	






CD8+	 T	 cells	 were	 incubated	with	 T2	 and	 T2A24	 cells	 pulsed	with	
HSP105	peptides	or	HLA	type‐matched	HIV	peptides	at	the	E/T	ratio	




in	 RPMI‐1640	 containing	 GlutaMax	 supplement	 (Thermo	 Fisher	
Scientific),	 10%	 human	 AB	 serum	 (Sigma),	 0.01%	 penicillin‐
streptomycin‐glutamine	 mixture	 (Thermo	 Fisher	 Scientific),	 2‐
mercaptoethanol	 (50	 μmol/L;	 Sigma),	 pyruvate	 (1	mmol/L;	 Gibco),	
and	 IL‐2	 (3000	 IU/mL)	 for	 14	 days	 at	 37°C	 and	 5%	 CO2.	 Tumor‐
infiltrating	 lymphocytes	 detected	 by	 the	 IFN‐γ	 ELISPOT	 assay	
were	incubated	with	HLA‐matched	HSP105	peptide‐pulsed	T2	and	
T2A24	 cells	 in	 the	 presence	 of	 APC‐conjugated	 anti‐CD107a	 Abs	
for	3.5	hours	at	37°C.	After	staining	with	FITC‐conjugated	anti‐CD8	
Abs	for	20	minutes	at	4°C,	TILs	were	analyzed	by	flow	cytometry.	





2.10 | Generation of CTL clones
The	 PBMC‐derived	 CD8+	 HSP105	 Dextramer+	 cells	 and	 tissue‐
derived	CD8+CD107a+	cells	were	sorted,	seeded	on	96‐well	plates	
(1	cell	per	well),	and	stimulated	with	 irradiated	 (100	Gy)	allogeneic	





Target	 cells	 labeled	 with	 calcein‐AM	 (Dojindo)	 for	 30	 minutes	 at	
37°C	were	cocultured	with	CTL	clones	for	4	hours	at	different	E/T	
ratios.	Fluorescence	was	measured	before	and	after	coculture	using	
the	 Terascan	 VPC	 system	 (Minerva	 Tech),	 and	 specific	 cytotoxic	
activity	was	calculated	as	previously	described.17
2.12 | Determination of recognition efficiency
Calcein‐AM‐labeled	T2	and	T2A24	cells	were	pulsed	with	different	
peptide	 concentrations	 (10−4‐10−14	 M	 at	 log	 increments)	 and	
incubated	with	CTL	clones	at	the	E/T	ratio	of	10.	After	4	hours,	CTLs	
were	 analyzed	 for	 recognition	 efficiency	 defined	 as	 the	 peptide	
concentration	 at	 which	 the	 concentration	 curve	 crosses	 the	 50%	
cytotoxicity	threshold.17
2.13 | Evaluation of HLA‐A2 restriction
Hepatitis	 B	 virus‐integrated	 human	 hepatocellular	 carcinoma	 cell	
line	 JHH‐7	 (low	 HSP105	 expression,	 HLA‐A*24:02+/A*31:01+)	
transfected	 with	 each	 HLA‐A2	 gene,	 JHH‐7/mock	 (HLA‐A2−),	
JHH‐7/A*02:01	 (HLA‐A*02:01+),	 JHH‐7/A*02:06	 (HLA‐A*02:06+),	
and	JHH‐7/A*02:07	(HLA‐A*02:07+)	was	used	as	the	target	cell	line.	






HSP105	 (clone	 EPR4576;	 Epitomics),	 HLA	 class	 I	 (clone	 EMR8‐5;	
Hokudo),	PD‐L1	(clone	SP142;	SPRING),	CD8	(clone	1A5;	BioGenex),	
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cells	 (67%	 or	 more),	 they	 were	 classified	 based	 on	 the	 intensity.	
Expression	of	PD‐L1	was	scored	as	–	(0%)	or	+	(1%	or	more)	according	
to	 the	 percentage	 of	 positively	 stained	 areas	 relative	 to	 the	 total	
tumor	areas.	CD4+	and	CD8+	T	cells	in	tumors	were	counted	in	high	
power	fields	(×400)	and	the	average	numbers	were	calculated.
2.15 | Sequence analysis of TCR
T‐cell	receptor	sequences	of	CTL	clones	were	identified	as	previously	










Statistical	 analyses	 were	 carried	 out	 using	 R	 software	 (The	 R	
Foundation	 for	 Statistical	 Computing;	 http://r‐proje	ct.org).	
Categorical	data	were	compared	by	the	χ2	test	or	Fisher's	exact	test,	
and	continuous	data	were	compared	by	the	Mann‐Whitney	U	 test.	





Clinicopathological	 characteristics	 of	 patients	 are	 presented	 in	
Table	1.	Among	the	30	patients,	21	were	men	and	17	and	13	were	
diagnosed	 with	 EC	 and	 CRC,	 respectively.	 The	 average	 age	 was	
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63.0	 years	 (range,	 30‐77	 years),	 and	 the	median	 follow‐up	 period	




We	evaluated	 the	 expression	 of	HSP105,	HLA	 class	 I,	 and	 PD‐L1	
in	primary	tumors	and	tumor	infiltration	of	CD4+	and	CD8+ T cells 
before	and	after	vaccination	(Tables	S2	and	S3	and	Figure	S2).	The	
expression	of	HSP105	and	HLA	class	 I	before	the	first	vaccination	
was	 observed	 in	 all	 analyzed	 patients	 (14/14,	 100%)	 and	 that	 of	
PD‐L1	was	detected	in	6	patients,	all	of	whom	had	EC.	Because	of	
objective	 difficulties	 in	 obtaining	 matching	 tumor	 samples	 before	
and	 after	 vaccination,	we	 could	 compare	 expression	 changes	only	









in	 11	 of	 30	 patients	 (37%);	 among	 them,	 7	 patients	 received	 the	
HLA‐A24	vaccine.	The	in	vitro	IFN‐γ	ELISPOT	results	showed	that	
HSP105	 peptide‐specific	 CTLs	 were	 induced	 in	 6	 patients	 (6/30,	
20%),	all	of	whom	received	the	HLA‐A2	vaccine.
3.3 | Heat shock protein 105‐specific CTLs could 
delay cancer progression and improve prognosis
We	 analyzed	 the	 correlation	 between	 HSP105‐specific	 CTL	
frequency	and	clinical	outcomes.	Mean	tumor	size	in	patients	with	
induced	HSP105‐specific	CTLs	(58.3	±	33.6	mm)	was	smaller	than	
that	 in	 patients	without	 the	 induction	 (88.7	 ±	 47.6	mm)	 (P	 =	 .04;	
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with	CTL	 frequencies	 less	 than	 100	 (0.94	 ±	 0.74;	P	 <	 .01).	 These	
data	 indicated	 that	 HSP105	 peptide	 vaccines	 might	 delay	 cancer	
progression	by	inducing	specific	CTLs	and	that	the	strength	of	the	
induction	was	 an	 important	 factor.	Moreover,	 the	CTL	 frequency	
also	correlated	with	OS	 (r	=	 .704,	P	<	 .01;	Figure	2C).	All	patients	
with	lower	spot	numbers	and	better	OS	(nos.	1,	8,	12,	15,	20,	and	










Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR P value HR 95% CI P value HR P value HR 95% CI P value
Age,	years	(≥65/<65) 1.14 .737    1.08 .856    
Sex	(male/female) 1.89 .143    1.06 .899    
Tumor	type	(EC/CRC) 1.54 .261    1.26 .593    
HLA	(A24/A2) 1.11 .786    2.02 .107    
Tumor	size	(≥50/<50) 1.14 .742    2.50 .060    
Performance	status	
(0/1)
1.94 .133 1.59 0.65‐3.91 .312 4.84 .004 4.39 1.43‐13.50 .010





3.21 .004 3.03 1.34‐6.85 .008 2.97 .013 2.72 1.13‐6.52 .025
CI,	confidence	interval;	CRC,	colorectal	cancer;	EC,	esophageal	cancer;	ELISPOT,	enzyme‐linked	immunospot;	HLA,	human	leukocyte	antigen;	HR,	
hazard	ratio;	IFN‐γ,	γ‐interferon.
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3.4 | Heat shock protein 105‐specific CTLs 
accumulated at vaccine inoculation sites and tumors
Next,	 we	 examined	 the	 infiltration	 of	 HSP105‐specific	 CTLs	 into	
vaccine	inoculation	sites	and	tumors	based	on	cytokine	production	




HSP105‐specific	CTLs	migrated	not	only	 to	 the	 injection	sites	but	





3.5 | Heat shock protein 105‐specific CTLs 
infiltrated into tumor tissue following peptide 
vaccination
In	 patient	 no.	 9,	 who	 was	 diagnosed	 with	 advanced	 EC	 and	 had	
the	HLA‐A*02:01	gene,	the	therapeutic	effect	was	classified	as	SD	
1	month	after	vaccination;	nevertheless,	he	developed	metastasis	to	
the	cervical	 lymph	node	and	vaccination	was	 terminated	after	 the	
fifth	 injection.	 The	 patient	 had	 insignificant	 increase	 of	 HSP105‐
specific	 CTLs	 ex	 vivo,	 but	 showed	 a	 remarkable	 induction	 of	
HSP105	A2‐7	peptide‐specific	CTLs	(246	of	5	×	105	PBMCs)	in	vitro	
(Figure	1).	We	 resected	 the	metastatic	 lymph	node	and	measured	
cytokine	release	by	infiltrated	HSP105	peptide‐specific	CTLs,	which	
showed	secretion	of	IL‐2,	IFN‐γ,	and	TNF‐α	(Figure	3).	Furthermore,	
immunohistochemistry	 revealed	 increased	 infiltration	 of	 CD8+ 
lymphocytes	 into	 the	 lymph	 node	 after	 vaccination	 (Figure	 4A	
and	 Table	 S3),	 indicating	 post‐vaccination	 changes	 in	 the	 tumor	
microenvironment.
To	assess	 the	 specificity	of	HSP105	 recognition	as	 an	antigen,	
TILs	from	lymph	node	tissue	were	incubated	with	high	concentration	
of	 IL‐2	 and	 analyzed	 for	 IFN‐γ	 production	 in	 response	 to	 T2	 cells	












Moreover,	 82.7%	 and	 4.16%	 of	 the	 cloned	 CTLs	 showed	 CD107a	




peptide	 and	 exerted	 cytotoxicity	 against	 cells	 presenting	HSP105	
not	 only	 exogenously	 but	 also	 endogenously.	 Furthermore,	 the	
CTL	clone	produced	 IFN‐γ	as	opposed	to	not	only	JHH‐7/A*02:01	
but	 also	 JHH‐7/A*02:06,	 showing	 that	 it	 could	 recognize	 not	 only	
HSP105	A2‐7	peptide‐HLA‐A*02:01	complex	but	also	A*02:06	com‐
plex	(Figure	S3).
3.6 | Heat shock protein 105‐specific CTL clone 
could recognize HSP105‐expressing cancer cells




A24‐1	 peptide‐specific	 CTLs	 (312	 of	 5	 ×	 105	 PBMCs)	 in	 the	 ex	
vivo	 IFN‐γ	 ELISPOT	 assay	 (Figure	 1)	 and	 established	 an	 A24‐1‐
specific	 CTL	 clone	 from	 a	 single	 CD8+HSP105	A24‐1	Dextramer+ 
cell	after	 the	third	vaccination	 (Figure	S4A).	The	CTL	clone,	which	
showed	 99.9%	 CD8/HSP105	 Dextramer	 positivity,	 demonstrated	
cytotoxicity,	cytokine	secretion,	and	CD107a	expression	specifically	
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against	 A24‐1‐pulsed	 T2A24	 cells	 and	 SW620	 cells;	 its	 A24‐1	
recognition	efficacy	was	10−8	M	(Figure	S4B‐F).
3.7 | Vaccine induced polyclonal peptide‐specific 
CTLs in PBMCs of vaccinated patients
We	 evaluated	 the	 clonality	 of	 peptide‐specific	 CTLs	 induced	
by	 vaccinations.	 Three	 other	 peptide‐specific	 CTL	 clones	 were	
established	 from	 the	 PBMCs	 of	 patient	 no.	 30	 (Figure	 S5A).	
Furthermore,	we	sorted	peptide‐specific	CTLs	(CD8+CD107a+	cells)	





(Table	 S6),	 suggesting	 that	 polyclonal	 peptide‐specific	 CTLs	 were	
induced	in	PBMCs	through	vaccination.
4  | DISCUSSION
Immune	 checkpoint	 inhibitors	 and	 adoptive	 immunotherapy	 with	
tumor‐infiltrating	 CTLs	 have	 shown	 undoubted	 efficacy	 against	
malignant	 melanoma.20,21	 Peptide	 vaccine	 therapy	 could	 prolong	
survival	 of	 cancer	patients	 and	prevent	 tumor	 recurrence	without	
serious	 adverse	effects,	 thus	not	 interfering	with	patient's	 quality	
of	 life.22	 However,	 it	 seems	 difficult	 to	 achieve	 an	 anticancer	
therapeutic	 effect	 using	 only	 peptide‐based	 vaccines.	 In	 this	 trial	
of	 the	HSP105	peptide	vaccine,	we	did	not	observe	patients	with	
complete	or	partial	response,	but	there	were	cases	with	 long‐term	
SD.	Our	 results	 indicate	 that	 the	HSP105	peptide	vaccine	 induces	
anticancer	 immune	 reactivity	 and,	 therefore,	 deserves	 further	
evaluation.	However,	 previous	 analyses	 of	 established	CTL	 clones	
revealed	their	antitumor	effects	on	HSP105+	cell	lines	were	limited,	
and	 the	 clinical	 effect	 of	 the	 vaccine	 was	 inadequate,	 probably	
because	 these	 CTLs	 were	 established	 from	 the	 cells	 of	 patients	





















creased survival.26‐28	 In	the	present	trial,	HSP105	expression	 in	tu‐
mors	decreased	after	 vaccination,	 suggesting	 that	 tumor	 cells	with	
high	HSP105	 levels	were	 removed,	 although	 those	with	 low	or	 no	
HSP105	expression	could	remain.	In	a	clinical	trial	of	a	GPC3‐target‐
ing	peptide	vaccine	as	adjuvant	therapy	for	hepatocellular	carcinoma,	





It	 should	 also	 be	 considered	 that	 tumor	 cells	 reduce	 their	 an‐




cells	 in	 a	 concentration‐dependent	 manner	 but	 also	 recognized	
HSP105‐expressing	 cells,	 thus	 showing	HSP105‐related	 antitumor	
activity.	However,	cytotoxicity	might	not	be	enough	to	achieve	clin‐
ical	 effectiveness	 because	 of	 insufficient	 antigen	 presentation	 by	
cancer	cells.	Although	we	detected	HSP105‐specific	CTLs	not	only	
at	the	injection	sites	but	also	in	2	metastatic	tumors	and	1	primary	
tumor,	 indicating	 that	 intradermal	 peptide	 vaccination	 promoted	
tumor	infiltration	by	CTLs,	it	is	not	sufficient	to	achieve	the	desired	
antitumor	 effects.	 To	 overcome	 this	 issue,	 we	 are	 developing	 an	




intratumoral	 peptide	 vaccination	with	 an	Ab	 blocking	PD‐1	 highly	
expressed	on	 the	surface	of	peptide‐specific	CTLs	augmented	an‐
ticancer	effects.34‐36	 It	 is	possible	that	vaccination	efficacy	can	be	









antigen	 specificity	 from	PBMCs	 after	vaccination.37‐39	Although	our	
CTL	clones	showed	similar	avidity	(10−7 and 10−8	M,	respectively),	the	
clone	obtained	using	the	CD107a	assay	tended	to	have	higher	pep‐





geting	 cancer	 antigens	 has	 reported	 significant	 long‐term	 clinical	
     |  3059SHIMIZU et al.





shown),	 suggesting	 that	 anticancer	 therapy	using	genetically	 engi‐
neered	CTLs	 has	 a	 potential	 in	 patients	with	HSP105‐positive	 tu‐
mors	of	different	HLA	types.
In	conclusion,	we	show	that	the	HSP105	peptide	vaccine	could	
induce	 functional	 tumor‐reactive	 CTLs	with	 high	HSP105‐peptide	
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